Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Melanoma and other skin tumours

5323 - (Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses

Date

11 Sep 2017

Session

Melanoma and other skin tumours

Presenters

Elisa Rozeman

Citation

Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377

Authors

E.A. Rozeman1, L. Fanchi2, A.C.J. van Akkooi3, P. Kvistborg2, J.V. Thienen1, B. Stegenga4, B. Lamon5, J.B. Haanen1, T.N.M. Schumacher2, C.U. Blank1

Author affiliations

  • 1 Medical Oncology Department, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 2 Department Of Molecular Oncology And Immunology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 3 Surigical Oncology Department, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 4 Immuno-oncology, Bristol-Meyers Squibb, 3502 HB - Utrecht/NL
  • 5 Immuno-oncology, Bristol-Myers Squibb, 08540 - Princeton/US
More

Resources

Abstract 5323

Background

The combination of IPI+NIVO induces high response rates and improved overall survival in late stage melanoma. T cell checkpoint inhibition is of greatest value at the moment of TCR triggering and therefore dependent on the amount of antigen present, indicating that adjuvant immunotherapy will work most efficiently, when initiated prior to surgery.

Methods

Two-arm Phase 1b feasibility trial consisting of 20 high risk AJCC stage 3B/C melanoma patients with palpable nodal disease receiving the combination of IPI 3mg/kg and NIVO 1mg/kg, either adjuvant four courses after surgery, or split neo-adjuvant and adjuvant.

Results

In this update 20 patients are evaluable. Neo-adjuvant application of IPI+NIVO was feasible and no surgery-associated adverse events were attributed to (neo-) adjuvant therapy. 18/20 patients had to stop earlier due to grade 3/4 toxicities. Neo-adjuvant IPI+NIVO reduced tumor load in 8/10 patients (3 pCR, 4 near pCRs [minimal remaining micro metastases], 1 pPR [

Conclusions

The combination of IPI+NIVO in the (neo-)adjuvant treatment setting for high risk stage 3 melanoma patients is promising and currently tested in an international phase 2 randomized trial comparing different combination schemes (OpACIN-neo trial, NCT02977052) with the aim of preserving efficacy, but reducing toxicity. Biomarkers identifying patients responding upon neo-adjuvant IPI+NIVO and remaining relapse-free for a long time, will help to select the patients that need to be exposed to IPI+NIVO associated toxicity.

Clinical trial identification

NCT02437279

Legal entity responsible for the study

NKI-AVL

Funding

Bristol-Myers Squib

Disclosure

P. Kvistborg: Advisory board: Neon therapeutics, Merck, Personalis. J.V. Thienen: Advisory board: MSD, Bristol-Myers Squibb. B. Stegenga, B. Lamon: Employee of Bristol-Myers Squibb. J.B. Haanen: Advisory role: Bristol-Myers Squibb, MSD, Pfizer, Roche, Novartis, Neon Therapeutics Research grants: Bristol-Myers Squibb, MSD, GSK. C.U. Blank: Advisory role: Bristol-Myers Squibb, MSD, GSK, Roche, Novartis, Lilly, Pfizer Research grants: Bristol-Myers Squibb, Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.